Eris Lifesciences has entered a strategic partnership with Natco Pharma Limited to commercialize Semaglutide in India, focusing on the expanding diabetes and metabolic care segment. Natco has received approval from the CDSCO for generic Semaglutide, paving the way for a launch in March 2026. Eris will leverage its strong commercial presence in diabetology, while Natco provides manufacturing expertise for this high-growth GLP-1 therapy.
Strategic Alliance for Metabolic Care
Eris Lifesciences Limited (BSE: 540596; NSE: ERIS), a leading Indian branded formulations company, announced a strategic partnership with Natco Pharma Limited for the commercialization of Semaglutide in India. This move reinforces Eris’s commitment to expanding its leadership within the fast-growing diabetes and metabolic care segment.
Semaglutide, identified as a transformative GLP-1 receptor agonist therapy, addresses Type 2 diabetes management and chronic weight management, areas experiencing rapidly increasing demand in India.
Partnership Details and Timeline
The collaboration capitalizes on complementary strengths: Eris’s robust commercial and diabetes franchise presence, and Natco’s manufacturing and regulatory prowess in complex formulations.
- Regulatory Milestone: Natco Pharma has secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market.
- Market Launch Focus: The product launch is anticipated in March 2026, targeting Type 2 diabetes management.
Leadership Perspective
Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, stated that Semaglutide represents one of the most significant therapeutic advances in metabolic care. He affirmed that Eris is well positioned to drive rapid adoption and enhance patient access through its strong commercial infrastructure and deep engagement in chronic therapies. The partnership is viewed as a long-term value driver for the company.
About Eris Lifesciences Ltd
Established in 2007, Eris is among the Top 20 pharma companies in India, boasting an annual branded formulations revenue exceeding INR 3,000+ Cr (as per AWACS). The company maintains a diversified presence across specialties including Diabetes, Cardiovascular, Neurology, and Oncology. Eris operates 6 manufacturing facilities and markets products through a network of approximately ~5,000 stockists and 5,00,000+ retail pharmacies.
The company’s revenue and operating profit have grown 2.6x in the last 5 years, with FY25 revenue reaching INR 2,894 Cr. Eris has invested approximately ~ INR 4,000 Cr over the last 3 years to diversify its presence across geographies and technologies.
Source: BSE
